| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/16/2023 | 181.37% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy |
| 08/21/2023 | 181.37% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy |
| 08/18/2023 | 1.29% | Guggenheim | $21 → $18 | Maintains | Neutral |
| 06/20/2023 | 237.65% | HC Wainwright & Co. | → $60 | Initiates Coverage On | → Buy |
| 03/01/2023 | 1.29% | Guggenheim | → $18 | Initiates Coverage On | → Neutral |
| 02/24/2023 | 344.57% | Citigroup | $76 → $79 | Maintains | Buy |
| 12/20/2021 | 248.9% | HC Wainwright & Co. | $52 → $62 | Maintains | Buy |
| 06/30/2020 | 57.57% | Stifel | → $28 | Initiates Coverage On | → Buy |
| 06/30/2020 | 147.61% | Jefferies | → $44 | Initiates Coverage On | → Buy |
What is the target price for Calliditas Therapeutics (CALT)?
The latest price target for Calliditas Therapeutics (NASDAQ: CALT) was reported by HC Wainwright & Co. on October 16, 2023. The analyst firm set a price target for $50.00 expecting CALT to rise to within 12 months (a possible 181.37% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Calliditas Therapeutics (CALT)?
The latest analyst rating for Calliditas Therapeutics (NASDAQ: CALT) was provided by HC Wainwright & Co., and Calliditas Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Calliditas Therapeutics (CALT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calliditas Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calliditas Therapeutics was filed on October 16, 2023 so you should expect the next rating to be made available sometime around October 16, 2024.
Is the Analyst Rating Calliditas Therapeutics (CALT) correct?
While ratings are subjective and will change, the latest Calliditas Therapeutics (CALT) rating was a reiterated with a price target of $50.00 to $50.00. The current price Calliditas Therapeutics (CALT) is trading at is $17.77, which is out of the analyst's predicted range.